Seoul, South Korea

Mi-Kyung Ji



 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Mi-Kyung Ji: Pioneering Treatments for Parkinson's Disease

Introduction: Mi-Kyung Ji is a notable inventor based in Seoul, South Korea, recognized for her contributions to the field of pharmaceuticals, specifically in the treatment of Parkinson's disease. With a focus on developing effective therapeutic compounds, her work exemplifies the impact of innovative research in improving patient outcomes.

Latest Patents: Mi-Kyung Ji holds a patent for "Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same." This patent includes descriptions of substituted azole derivatives and their pharmaceutically acceptable salts, demonstrating efficacy against Parkinson's disease through the inhibitory effects on MAO-B activity. The method involves administering an effective amount of the compound to a mammal, highlighting its potential therapeutic applications.

Career Highlights: Mi-Kyung Ji is currently associated with SK Biopharmaceuticals Co., Ltd., where she contributes innovative ideas and research to the pharmaceutical sector. Her dedication to advancing knowledge in drug development has led to significant strides in addressing neurological disorders, particularly Parkinson's disease.

Collaborations: Throughout her career, Mi-Kyung Ji has collaborated with esteemed colleagues such as Cheol-Hyoung Park and Hye-Kyung Min. These partnerships reflect her commitment to teamwork and drive for scientific discovery, enhancing the potential for groundbreaking developments in medical treatments.

Conclusion: Mi-Kyung Ji's work exemplifies the power of innovation in the pharmaceutical industry. Her patent addressing Parkinson's disease not only showcases her inventive spirit but also underscores the importance of continued research to improve therapeutic options for patients. As Mi-Kyung Ji continues her work at SK Biopharmaceuticals Co., Ltd., the medical community eagerly anticipates further advancements stemming from her innovative contributions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…